AstraZeneca's Breakthrough in COPD Treatment Raises Questions on Competition and Patient Care AstraZeneca's recent release of full data from two successful late stage trials on its experimental drug, tozorakimab, has generated significant buzz in the pharmaceutical industry.
The biologic medicine has shown promising results in reducing flare ups in a broad range of patients with chronic obstructive pulmonary disease (COPD), including those with lower eosinophil counts who are often excluded from treatment with currently available biologics.
The data is encouraging, but it also raises important questions about how tozorakimab will fit into the existing treatment landscape for COPD.